HIV

Hongxiang Chen of Union Hospital, Tongji Medical College, Huazhong University in China will develop X-ray-sensitive fluorescent nanoparticles conjugated to antibodies that will selectively bind to HIV. Once bound to the targets, the nanoparticles can be excited by X-rays to kill the virus.

Marc-Andre Langlois of the University of Ottawa in Canada will develop small molecules that combine together to form a toxic compound only when they enter an HIV-infected cell. Because the molecules are non-toxic for healthy cells, they could constitute promising candidates for a vaccine-based delivery system aimed at specifically eliminating HIV-infected cells.

Nicolas Chomont of the Vaccine & Gene Therapy Institute Florida in the U.S. will determine if the stimulation of latently infected cells with HIV antigens is a viable strategy for eradicating the HIV reservoir. If successful, the strategy could be used to cure HIV by combining HAART and immunization with HIV antigens.

Fabio Romerio of the University of Maryland, Baltimore in the U.S. seeks to identify surface biomarkers of HIV latently infected cells by comparing membrane proteomes of latently infected and uninfected cells. Unique biomarkers allow selective killing of latently infected cells with specific ligands, or targeted delivery of chemotherapeutic agents.

Ekaterina Dadachova of the Albert Einstein College of Medicine in the U.S., in collaboration with Arturo Casadevall, proposes to use radioimmunotherapy as a strategy to eliminate HIV-infected cells in patients on anti-retroviral therapy. Targeting viral antigens on these cells with radioactivity-armed antibodies could lead to HIV eradication. This project's Phase I research demonstrated that radioimmunotherapy can kill HIV-infected primary human cells in conjunction with anti-retroviral therapy (ART) and that this antibody can also reach HIV-infected cells in the central nervous system.

Amalio Telenti of the Institute of Microbiology in Switzerland proposes to identify biomarkers specific to HIV latency using high-throughput screening of RNA sequences and a customized screening tool for validating HIV positive individuals. If successful, the biomarkers could be used in the study of HIV latency reservoirs and aid eradication efforts.

Sara Richter of the University of Padua in Italy will develop a therapeutic to completely clear HIV from the body by targeting a proviral DNA structural motif found in both actively and latently infected host cells. In Phase I they analyzed a highly conserved DNA structural motif of four guanine nucleotides (G-4) found in the integrated HIV-1 proviral DNA and found that it regulates proviral transcription and is likely involved in latent infection.

Jerome Zack of the University of California, Los Angeles in the U.S. will test nanoparticles for their ability to specifically activate HIV from latently infected cells. Once the latent cells express viral proteins, host immune responses and targeted therapies can be used to kill the cell. If successful, this project could provide an effective approach to eliminate an important viral reservoir from HIV infected individuals.

Alex Deiters of North Carolina State University in the U.S. will work to discover small molecule inhibitors of short ribonucleic acids (microRNAs) that cause HIV latency in resting T-lymphocytes. Inhibiting the function of these microRNAs could reverse HIV latency, purge HIV reservoirs, and ultimately represent a chemotherapeutic approach to eradicating HIV infection.

Joao Goncalves of ADEIM - Faculdade de Farmacia Lisboa in Portugal proposes to develop molecular sensor strategies using nanoparticles to target memory T cells to deliver a toxin that will be expressed when zinc-finger proteins detect HIV-1 sequences.